KN

Kanabo Group PLCLSE Kanabo Group Stock Report

Last reporting period 30 Jun, 2024

Updated 01 Nov, 2024

Last price

Market cap $B

0.01

Micro

Exchange

XLON - London Stock Exchange

KNB.L Stock Analysis

KN

Uncovered

Kanabo Group PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-46/100

Low score

Market cap $B

0.01

Dividend yield

Shares outstanding

422.92 B

Kanabo Group Plc engages in the acquisition of a target company and business in the energy and industrial sectors. The firm focuses on the distribution of cannabis-derived products for medical patients, and non-tetrahydrocannabinol (THC) products for cannabidiol (CBD) consumers. The company has developed over the counter (OTC) formulas, which target the growing CBD market globally. Its OTC formulas include a broad spectrum of cannabis oil. Its first formula targeted insomnia and sleep disorders. In addition to the initial formula targeting sleep disorders, the Company is developing formulas to target chronic pain and anxiety, with a focus on post-traumatic stress disorder (PTSD). Its formulas are made with a carrier solution that replaces traditional electronic cigarette liquids like PG/VG and MCT oil diluents. The firm is also engaged in the development and acquisition of cannabis-related businesses and production assets in the United Kingdom and abroad.

View Section: Eyestock Rating